Document is current
Any future updates will be listed below
-
Authors
Ebrahimi-Nik, Hakimeh
Baumgartner, Christina K
Iracheta-Vellve, Arvin
Hamel, Keith M
Olander, Kira
Davis, Thomas GR
McGuire, Kathleen A
Halvorsen, Geoff T
Avila, Omar I
Patel, Chirag
Kim, Sarah
Kammula, Ashwin V
Muscato, Audrey J
Halliwill, Kyle
Geda, Prasanthi
Klinge, Kelly
Xiong, Zhaoming
Duggan, Ryan
Mu, Liang
Yeary, Mitchell D
Patti, James C
Balon, Tyler M
Mathew, Rebecca
Backus, Carey
Kennedy, Domenick
Chen, Angeline
Longenecker, Kenton
Klahn, Joseph
Hrusch, Cara
Krishnan, Navasona
Hutchins, Charles W
Aguado, Jacqueline
Bulic, Marinka
Tiwari, Payal
Colvin, Kayla J
Chuong, Cun Lan
Kohnle, Ian C
Rees, Matthew G
Boghossian, Andrew
Ronan, Melissa
Roth, Jennifer A
Wu, Meng-Ju
Sen, Debattama R
Griffin, Gabriel K
El-Bardeesy, Nabeel
Trusk, Patricia
Sun, Meng
Liu, Yue
Decker, Joshua H
Yang, Yi
Fossey, Stacey
Qiu, Wei
Sun, Qi
Paddock, Marcia N
Farney, Elliot P
Beauregard, Clay
Frost, Jennifer M
Yates, Kathleen B
Kym, Philip R
Manguso, Robert T
-
Clinical Trials BETA
Clinical trials referenced in this document:
nct04777994 at ClinicalTrials.govDocuments that mention this clinical trial
CXCR3 signaling promotes Delta One T cell recruitment and antitumor efficacy in colorectal cancer
https://doi.org/10.1136/jitc-2025-014668
1403-A PTPN2/N1 inhibitor ABBV-CLS-484 unleashes potent anti-tumor immunity
https://doi.org/10.1136/jitc-2023-sitc2023.1403-a
311 Inhibition of PTPN2/N1 by the small molecule inhibitor ABBV-CLS-484 enhances the efficacy of adoptive T cell therapy
https://doi.org/10.1136/jitc-2025-sitc2025.0311
- License Information
